Developing a drug-inducible gene therapy for temporal lobe epilepsy
开发药物诱导的颞叶癫痫基因疗法
基本信息
- 批准号:9156597
- 负责人:
- 金额:$ 34.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-01 至 2020-04-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsAffectAmericanAmygdaloid structureAnimal ModelAnimalsAntibioticsAntiepileptic AgentsBasic ScienceBehavioralBehavioral AssayBiological AssayBiological MarkersBrainBrain InjuriesBrain regionChronicClinicalClinical ResearchClinical TrialsControl AnimalCortical DysplasiaDataData AnalysesDependovirusDevelopmentDiseaseDoseDoxycyclineEffectivenessElectric StimulationElectroencephalographyEpilepsyExcisionFocal SeizureFoundationsFrequenciesFrightFundingFutureGene DeliveryGenesGrantGuidelinesHippocampus (Brain)HumanImageInfusion proceduresInjection of therapeutic agentLearningLeftMagnetic Resonance ImagingMeasuresMedicalMedicineMemoryMethodsModelingMonitorNational Institute of Neurological Disorders and StrokeNeurologicNeuronsNeurosurgeonOperative Surgical ProceduresOutputPartial EpilepsiesPathologyPatientsPharmaceutical PreparationsPharmacotherapyPhysiologyPotassium ChannelPublishingRadialRandomizedRattusRecombinant adeno-associated virus (rAAV)ResearchRestRisk-TakingRodentSafetySample SizeSeizuresSeveritiesSiteSourceStatus EpilepticusTemporal LobeTemporal Lobe EpilepsyTestingThalamic structureTherapeuticTimeTitrationsTranslational ResearchTranslationsTraumatic Brain InjuryUniversitiesVirginiaarmentorhinal cortexgene therapyimage guidedimprovedimproved functioninginnovationmorris water mazeneuron lossnovelnovel therapeuticspreclinical studypreventsafety testingspatial memorytool
项目摘要
There are 3 million Americans with epilepsy. This research aims to develop first-in-class drug-
inducible gene therapies for the most common form of focal epilepsy, temporal lobe epilepsy (TLE),
which affects half a million Americans. Despite the size of this problem, medical treatment of TLE fails
in 35% of these patients, leaving a large unmet clinical need. For over 40 years, the only option left for
some of these patients has been surgical resection of the temporal lobe. Although this reduces
seizures, it has many problems. One, it is not a cure, so most patients must continue to take antiepileptic
drugs with attendant side effects. Two, many patients are unwilling to take the risk of permanent brain
damage, such as impaired learning and memory. TLE is one of the best studied forms of epilepsy and
there are excellent animal models of TLE that can be used to test novel therapies. The overarching
hypothesis of this grant is that by silencing critical neurons in the epileptic circuit with gene therapy,
one can effectively stop seizures cold. This approach could be extended to other types of focal
seizures, such as: focal cortical dysplasia and epilepsy after traumatic brain injury. Notably, this
treatment could be used on patients for whom surgery is not an option due to fear of neurological
deficits, those with multiple seizure foci or when the focus is in a critical, or “eloquent” region of the
cortex. To address this critical unmet need, this grant will develop novel gene therapies based on
recombinant adeno-associated virus (AAV). Advances in imaging and EEG source localization already
allow doctors to localize seizure foci almost to the cellular level. Imagine a future when, rather than
cutting, neurosurgeons inject AAV to disrupt the seizure from spreading to the rest of the brain. In fact,
magnetic resonance imaging (MRI)-guided delivery of therapeutics has already been shown to be an
effective method for targeting specific brain regions. Using funds from the CURE Foundation,
preliminary data was collected that show AAV delivery of a modified leak K+ channel (TREK-M) reduces
status epilepticus. Importantly, the gene therapy reduced spontaneous recurring seizures by 90% in a
rat model of TLE. Aim 1 will compare injection of TREK-M at different sites and study its effect on
spontaneous seizures in a chronic TLE rat model. Aim 2 will test the safety of the gene therapy in
control animals and whether TREK-M can correct seizure-induced deficits in learning and memory. Aim
3 is a preclinical study to establish the efficacy of the gene therapy on spontaneous recurring seizures
in a rat model of TLE. We predict drug-inducible gene therapy will have a large impact on both clinical
and basic research.
美国有300万癫痫患者。这项研究旨在开发一流的药物-
用于最常见形式的局灶性癫痫,颞叶癫痫(TLE),
影响了五十万美国人尽管这个问题的规模,TLE的药物治疗失败
在这些患者中,有35%的人,留下了大量未满足的临床需求。40多年来,唯一的选择是
其中部分患者已手术切除颞叶。虽然这减少了
癫痫发作,它有很多问题。第一,它不是一种治愈方法,因此大多数患者必须继续服用抗癫痫药
有副作用的药物二、很多患者不愿意冒永久性脑溢血的风险
损害,如学习和记忆受损。TLE是癫痫的最佳研究形式之一,
有很好的TLE动物模型可用于测试新疗法。总体
这项资助的假设是,通过基因治疗沉默癫痫回路中的关键神经元,
可以有效地阻止感冒发作。这种方法可以扩展到其他类型的焦点
癫痫发作,如:局灶性皮质发育不良和创伤性脑损伤后癫痫。值得注意的是,
治疗可以用于那些由于害怕神经系统疾病而无法选择手术的患者,
缺陷,具有多个癫痫灶或当焦点位于关键或“雄辩”区域时,
皮层为了解决这一关键的未满足的需求,这笔赠款将开发新的基因疗法,
重组腺相关病毒(AAV)。成像和脑电源定位方面的进展已经
使医生能够将癫痫病灶定位到细胞水平。想象一个未来,
神经外科医生注射AAV来阻止癫痫蔓延到大脑的其他部分。事实上,
磁共振成像(MRI)引导的治疗剂递送已经被证明是一种
针对特定大脑区域的有效方法。利用CURE基金会的资金,
收集的初步数据显示,修饰的渗漏K+通道(TREK-M)的AAV递送降低了
癫痫持续状态重要的是,基因治疗减少了90%的自发复发性癫痫发作,
TLE大鼠模型。目的1:比较不同部位注射TREK-M,研究其对
慢性TLE大鼠模型中的自发性癫痫发作。目标2将测试基因治疗在以下方面的安全性:
对照动物以及TREK-M是否可以纠正癫痫诱导的学习和记忆缺陷。目的
3是一项临床前研究,旨在确定基因治疗对自发复发性癫痫发作的疗效
在TLE大鼠模型中。我们预测药物诱导基因治疗将对临床和基因治疗产生巨大影响。
和基础研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EDWARD PEREZ-REYES其他文献
EDWARD PEREZ-REYES的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EDWARD PEREZ-REYES', 18)}}的其他基金
Validation of a novel mouse model of temporal lobe epilepsy
新型颞叶癫痫小鼠模型的验证
- 批准号:
9810436 - 财政年份:2019
- 资助金额:
$ 34.56万 - 项目类别:
Validation of a Novel Mouse Model of Temporal Lobe Epilepsy
颞叶癫痫新型小鼠模型的验证
- 批准号:
10618726 - 财政年份:2019
- 资助金额:
$ 34.56万 - 项目类别:
Developing a drug-inducible gene therapy for temporal lobe epilepsy
开发药物诱导的颞叶癫痫基因疗法
- 批准号:
10800000 - 财政年份:2016
- 资助金额:
$ 34.56万 - 项目类别:
Probing epileptic circuits with novel Cre- and drug-regulated genetic approaches
用新型 Cre 和药物调节的遗传方法探索癫痫回路
- 批准号:
8913446 - 财政年份:2015
- 资助金额:
$ 34.56万 - 项目类别:
Neuron-specific block of T-type calcium channels
T 型钙通道的神经元特异性阻断
- 批准号:
8235787 - 财政年份:2011
- 资助金额:
$ 34.56万 - 项目类别:
Neuron-specific block of T-type calcium channels
T 型钙通道的神经元特异性阻断
- 批准号:
8117447 - 财政年份:2011
- 资助金额:
$ 34.56万 - 项目类别:
Mechanisms by which T-type calcium channels increase seizure susceptibility
T型钙通道增加癫痫易感性的机制
- 批准号:
7776541 - 财政年份:2009
- 资助金额:
$ 34.56万 - 项目类别:
Development of High Throughput Assays for HVA CA Channels
HVA CA 通道高通量检测的开发
- 批准号:
7049771 - 财政年份:2006
- 资助金额:
$ 34.56万 - 项目类别:
Development of High Throughput Assays for N-type Calcium Channels
N 型钙通道高通量检测的开发
- 批准号:
7345651 - 财政年份:2006
- 资助金额:
$ 34.56万 - 项目类别:
MOLECULAR ANALYSIS OF NEURONAL T TYPE CALCIUM CHANNELS
神经元 T 型钙通道的分子分析
- 批准号:
2842883 - 财政年份:1999
- 资助金额:
$ 34.56万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 34.56万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 34.56万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 34.56万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 34.56万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 34.56万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 34.56万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 34.56万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 34.56万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 34.56万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 34.56万 - 项目类别:
Discovery Grants Program - Individual